Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518129

— · C

a9df3ba7-8a99-5336-85a8-5680e4ad0eb3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.530
  • INTERFERON_GAMMA_RESPONSE+0.480
  • ALLOGRAFT_REJECTION+0.290
  • OXIDATIVE_PHOSPHORYLATION+0.230
  • PANCREAS_BETA_CELLS+0.190
  • FATTY_ACID_METABOLISM+0.180
  • APOPTOSIS+0.160
  • BILE_ACID_METABOLISM+0.140
  • UNFOLDED_PROTEIN_RESPONSE+0.140
  • MTORC1_SIGNALING+0.120

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.330
  • G2M_CHECKPOINT-0.270
  • HYPOXIA-0.260
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
  • E2F_TARGETS-0.220
  • NOTCH_SIGNALING-0.210
  • MYOGENESIS-0.180
  • ANGIOGENESIS-0.160
  • CHOLESTEROL_HOMEOSTASIS-0.160
  • HEME_METABOLISM-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR2660032
melanoma-umap@29
——0.758
2SRR8518342
breast-umap@18
—F0.749
3s0112210
melanoma-umap@29
——0.733
420040027.LumB
breast-umap@18
—C0.720
5TCGA-BH-A6R8-01A-21R-A33J-07
breast-umap@18
—B0.713
6TCGA-BH-A0BT-01A-11R-A12P-07
breast-umap@18
—B0.705
7399e5b76-1d8d-4db9-a186-ffdc2f6e0884
melanoma-umap@29
——0.698
820050094.LumB
breast-umap@18
—B0.698
9TCGA-OL-A66H-01A-11R-A29R-07
breast-umap@18
—B0.698
10TCGA-E2-A1IK-01A-11R-A144-07
breast-umap@18
—B0.686

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.530Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.480Idelalisib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.230Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.190Cobimetinib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
APOPTOSIS0.160Idelalisib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.140Idelalisib— uncovered
MTORC1_SIGNALING0.120Inavolisib— uncovered
MYC_TARGETS_V20.120Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.060Idelalisib— uncovered
P53_PATHWAY0.060Idelalisib— uncovered
PEROXISOME0.060Idelalisib— uncovered
COMPLEMENT0.050Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.040Idelalisib— uncovered